Sequoia Financial Advisors LLC Invests $732,000 in Ascendis Pharma A/S (NASDAQ:ASND)

Sequoia Financial Advisors LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 5,811 shares of the biotechnology company's stock, valued at approximately $732,000.

Other large investors have also recently modified their holdings of the company. Envestnet Asset Management Inc. grew its position in Ascendis Pharma A/S by 3.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 3,226 shares of the biotechnology company's stock valued at $333,000 after acquiring an additional 105 shares during the last quarter. Guggenheim Capital LLC grew its position in shares of Ascendis Pharma A/S by 7.2% during the 1st quarter. Guggenheim Capital LLC now owns 2,008 shares of the biotechnology company's stock worth $236,000 after buying an additional 135 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Ascendis Pharma A/S by 1.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,989 shares of the biotechnology company's stock worth $1,762,000 after buying an additional 186 shares in the last quarter. Signaturefd LLC grew its position in shares of Ascendis Pharma A/S by 31.9% during the 3rd quarter. Signaturefd LLC now owns 798 shares of the biotechnology company's stock worth $75,000 after buying an additional 193 shares in the last quarter. Finally, SkyView Investment Advisors LLC bought a new position in shares of Ascendis Pharma A/S during the 2nd quarter worth $66,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ASND shares. Citigroup increased their price target on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a "buy" rating in a research report on Thursday, February 8th. Jefferies Financial Group started coverage on Ascendis Pharma A/S in a report on Wednesday, December 20th. They issued a "buy" rating and a $150.00 price objective on the stock. Wells Fargo & Company raised their target price on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an "overweight" rating in a report on Friday, March 15th. StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a report on Monday, December 25th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, April 1st. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $173.25.

Ascendis Pharma A/S Stock Down 2.6 %

Shares of ASND traded down $3.73 on Tuesday, reaching $141.50. The stock had a trading volume of 367,491 shares, compared to its average volume of 377,866. The firm has a market capitalization of $8.24 billion, a PE ratio of -15.30 and a beta of 0.50. The firm has a 50-day moving average of $149.11 and a 200 day moving average of $123.62. Ascendis Pharma A/S has a twelve month low of $66.03 and a twelve month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, topping analysts' consensus estimates of ($2.15) by $0.49. The business had revenue of $148.62 million for the quarter, compared to analysts' expectations of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post -4.18 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.